GaryWalterUnzeitigMD

General Surgery • Laredo, TX

Physician

Join to view full profile

Dr. Unzeitig is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Unzeitig's full profile

Already have an account?

Office
6801 Mcpherson Rd Ste 106
Laredo, TX 78041
Phone+1 956-726-3691

Fax+1 956-726-3692
Is this information wrong?

Education & Training

Kaiser Permanente Southern California (Los Angeles)Residency, Surgery, 1980 - 1983
University of Southern California/LAC+USC Medical CenterInternship, Surgery, 1978 - 1979
Northwestern University The Feinberg School of MedicineClass of 1978

Certifications & Licensure

CA State Medical License 1979 - Present
TX State Medical License 1983 - 2025
American Board of Surgery Surgery

Awards, Honors, & Recognition

Humanitarian award ASCO, 2020
Richard Schilsky Award ALLIANCE for Clinical Trials in Oncology, 2018
Clinical Trials Participation Award ASCO, 2009, 2014
Laredoan of the Year Laredo Morning Times, 2013
Fellow (FACS) American College of Surgeons
Super Doctor SuperDoctors.com
Join now to see all

Clinical Trials

Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial) Start of enrollment: 2006 Apr 07
Active, not recruiting
Phase 3
Education With or Without Exercise and Counseling in Preventing Lymphedema in Women With Stage I, Stage II, or Stage III Breast Cancer Who Are Undergoing Axillary Lymph Node Dissection Start of enrollment: 2006 Jun 01
Completed
Phase 3
Combination Chemotherapy and Paclitaxel Plus Trastuzumab in Treating Women With Palpable Breast Cancer That Can Be Removed by Surgery Start of enrollment: 2007 Jul 01
Completed
Phase 3
Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy Start of enrollment: 2008 Nov 10
Active, not recruiting
Phase 3
Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery Start of enrollment: 2009 May 15
Active, not recruiting
Phase 2
Rosuvastatin in Treating Patients With Stage I or Stage II Colon Cancer That Was Removed By Surgery Start of enrollment: 2010 Mar 01
Terminated
Phase 3
S0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer Start of enrollment: 2011 Nov 01
Completed
Not Applicable
A Phase III Randomized Trial of Metformin vs Placebo in Early Stage Breast Cancer Start of enrollment: 2010 Aug 13
Completed
Phase 3
Vitamin D and Breast Cancer Biomarkers in Female Patients Start of enrollment: 2010 Oct 01
Completed
Phase 3
Early Surgery or Standard Palliative Therapy in Treating Patients With Stage IV Breast Cancer Start of enrollment: 2011 May 16
Completed
Not Applicable
Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer Start of enrollment: 2011 Jan 15
Active, not recruiting
Phase 3
Breast-Conserving Surgery and Radiation Therapy in Patients With Multiple Ipsilateral Breast Cancer Start of enrollment: 2012 Jul 01
Completed
Phase 2
S1202: Duloxetine Hydrochloride for Muscle/Joint Pain in Early-Stage Breast Cancer Receiving Hormone Therapy Start of enrollment: 2013 May 15
Completed
Phase 3
S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer Start of enrollment: 2013 Sep 12
Active, not recruiting
Phase 3
Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer Start of enrollment: 2014 Jan 15
Active, not recruiting
Phase 3
Molecular Genetics Studies of Cancer Patients and Their Relatives Start of enrollment: 1997 Apr 18
Recruiting
Roles: Principal Investigator, Contact
Join now to see all

Publications & Presentations

PubMed

Endocrine-Sensitive Disease Rate in Postmenopausal Patients With Estrogen Receptor-Rich/ERBB2-Negative Breast Cancer Receiving Neoadjuvant Anastrozole, Fulvestrant, or...
Cynthia X Ma, Vera J Suman, Souzan Sanati, Kiran Vij, Meenakshi Anurag, A Marilyn Leitch, Gary W Unzeitig, Jeremy Hoog, Aranzazu Fernandez-Martinez, Cheng Fan, Richard...> ;JAMA Oncology. 2024 Mar 1
ASO Visual Abstract: Local-Regional Recurrence Following Neoadjuvant Endocrine Therapy - Data from ACOSOG Z1031 (Alliance), a Randomized Phase II Neoadjuvant Compariso...
Kelly K Hunt, Vera J Suman, Hannah F Wingate, A Marilyn Leitch, Gary Unzeitig, Judy C Boughey, Funda Meric-Bernstam, Matthew J Ellis, John A Olson> ;Annals of Surgical Oncology. 2023 Apr 1
2 citations
Local-Regional Recurrence After Neoadjuvant Endocrine Therapy: Data from ACOSOG Z1031 (Alliance), a Randomized Phase 2 Neoadjuvant Comparison Between Letrozole, Anastr...
Kelly K Hunt, Vera J Suman, Hannah F Wingate, A Marilyn Leitch, Gary Unzeitig, Judy C Boughey, Funda Meric-Bernstam, Matthew J Ellis, John Olson> ;Annals of Surgical Oncology. 2023 Apr 1
5 citations
The Influence of Vitamin D on Mammographic Density: Results from CALGB 70806 (Alliance) a Randomized Clinical Trial.
Marie E. Wood, Heshan Liu, Elizabeth Storrick, David Zahrieh, H. Carisa Le-Petross, Sin-Ho Jung, Patricia J. Zekan, Margaret Kemeny, Jayne R. Charlamb, Lili X. Wang, G...> ;Cancer Prevention Research. 2021 Apr 13
10 citations
A randomized study to prevent lymphedema in women treated for breast cancer: CALGB 70305 (Alliance)
Electra D. Paskett, Jennifer Le-Rademacher, Jill M. Oliveri, Heshan Liu, Drew K. Seisler, Jeff A. Sloan, Jane M. Armer, Michelle J. Naughton, Karen Hock, Michael Schwa...> ;Cancer. 2021 Jan 15
9 citations
Health-related quality of life outcomes for the LEAP study—CALGB 70305 (Alliance): A lymphedema prevention intervention trial for newly diagnosed breast cancer patients
Michelle J. Naughton, Heshan Liu, Drew K. Seisler, Jennifer Le-Rademacher, Jane M. Armer, Jill M. Oliveri, Jeff A. Sloan, Karen Hock, Michael Schwartz, Gary Unzeitig, ...> ;Cancer. 2021 Jan 15
4 citations
Clinical Trials for the Surgical Oncologist: Opportunities and Hurdles
Ko Un Park, Eleftherios P. Mamounas, Matthew H.G. Katz, Gary Unzeitig, Darren R. Carpizo, Y. Nancy You, Amanda B. Francescatti, Kelly K. Hunt, Judy C. Boughey> ;Annals of Surgical Oncology. 2020 Jul 1
209 citations
Cancer Risks Associated With Germline PALB2 Pathogenic Variants: An International Study of 524 Families
Xin Yang, Goska Leslie, Alicja Doroszuk, Sandra Schneider, Jamie Allen, Brennan Decker, Alison M. Dunning, James E. Redman, James Scarth, Inga Plaskocinska, Craig Lucc...> ;Journal of Clinical Oncology. 2020 Mar 1
33 citations
Pathogenic and likely pathogenic variants in PALB2, CHEK2, and other known breast cancer susceptibility genes among 1054 BRCA-negative Hispanics with breast cancer
Jeffrey N. Weitzel, Susan L. Neuhausen, Aaron Adamson, Shu Tao, Charité Ricker, Asaf Maoz, Margalit Rosenblatt, Bita Nehoray, Sharon Sand, Linda Steele, Gary Unzeitig,...> ;Cancer. 2019 Aug 15
10 citations
Disease-Free and Overall Survival Among Patients With Operable HER2-Positive Breast Cancer Treated With Sequential vs Concurrent Chemotherapy: The ACOSOG Z1041 (Allian...
Aman U. Buzdar, Vera J. Suman, Funda Meric-Bernstam, A. M. Leitch, Matthew J. Ellis, Judy C. Boughey, Gary Unzeitig, Melanie Royce, Kelly K. Hunt> ;JAMA Oncology. 2019 Jan 1
11 citations
Hispanic breast cancer patients' symptom experience and patient-physician communication during chemotherapy.
Jessica L. Krok-Schoen, Katia Fernandez, Gary W. Unzeitig, Griselda Rubio, Electra D. Paskett, Douglas M. Post> ;Supportive Care in Cancer. 2019 Feb 1
41 citations
Genomic characterization of HER2-positive breast cancer and response to neoadjuvant trastuzumab and chemotherapy—results from the ACOSOG Z1041 (Alliance) trial
Robert Lesurf, Obi L. Griffith, Malachi Griffith, Jasreet Hundal, Lee Trani, Mark A. Watson, Rebecca Aft, MJ Ellis, David M. Ota, Vera J. Suman, Funda Meric-Bernstam, ...> ;Annals of Oncology. 2017 May 1
203 citations
Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American Co...
Matthew J. Ellis, Vera J. Suman, Jeremy Hoog, Rodrigo Franco Gonçalves, Souzan Sanati, Chad J. Creighton, Katherine DeSchryver, Erika C. Crouch, Amy Brink, Mark A. Wat...> ;Journal of Clinical Oncology. 2017 Apr 1
2 citations
Effect of Vitamin D Supplementation on Breast Cancer Biomarkers: CALGB 70806 (Alliance) Study Design and Baseline Data.
Ogheneruona Apoe, Sin-Ho Jung, Heshan Liu, Drew K. Seisler, Jayne R. Charlamb, Patricia J. Zekan, Lili X. Wang, Gary Unzeitig, Judy Garber, James R. Marshall, Marie E....> ;American Journal of Hematology/oncology. 2016 Jul 1
123 citations
Fluorouracil, epirubicin, and cyclophosphamide (FEC-75) followed by paclitaxel plus trastuzumab versus paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab ...
Aman U. Buzdar, Vera J. Suman, Funda Meric-Bernstam, A. Marilyn Leitch, Matthew J. Ellis, Judy C. Boughey, Gary Unzeitig, Melanie Royce, Linda M. McCall, Michael S. Ew...> ;The Lancet. Oncology. 2013 Dec 1
114 citations
Prevalence and Type of BRCA Mutations in Hispanics Undergoing Genetic Cancer Risk Assessment in the Southwestern United States: A Report From the Clinical Cancer Genet...
Jeffrey N. Weitzel, Jessica Clague, Arelis E. Martir-Negron, Raquel Ogaz, Josef Herzog, Charité Ricker, Chelsy R. Jungbluth, Cheryl Cina, Paul Duncan, Gary Unzeitig, J...> ;Journal of Clinical Oncology. 2013 Jan 10
771 citations
Whole-genome analysis informs breast cancer response to aromatase inhibition
Matthew J. Ellis, Li Ding, Dong Shen, Jingqin Luo, Vera J. Suman, John W. Wallis, Brian A. Van Tine, Jeremy Hoog, Reece J. Goiffon, Theodore C. Goldstein, Sam Ng, Li L...> ;Nature. 2012 Jun 21
American College of Surgeons Oncology Group and the community surgeon.
David M. Ota, A. Marilyn Leitch, Gary Unzeitig> ;Surgical Oncology Clinics of North America. 2011 Jul 1
347 citations
Randomized Phase II Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women With Estrogen Receptor–Rich Stage 2 to 3 Breast Canc...
Matthew J. Ellis, Vera J. Suman, Jeremy Hoog, Li Lin, Jacqueline E. Snider, Aleix Prat, Joel S. Parker, Jingqin Luo, Katherine DeSchryver, D. Craig Allred, Laura J. Es...> ;Journal of Clinical Oncology. 2011 Jun 10
1 citations
How a surgeon in the boonies becomes a researcher and regional expert.
Gary Unzeitig> ;Bulletin of the American College of Surgeons. 2007 Dec 1
11 citations
Analysis of the prognosis of minimal and occult breast cancers.
Gary W. Unzeitig, Gloria Frankl, Mona Ackerman, Theodore X. O'Connell> ;Archives of Surgery. 1983 Dec 1
Join now to see all

Lectures

Community Participation in Trials
Laredo, TX - 10/28/2014

Press Mentions

Cancer Care by Zip Code: Examining Geographic Health Disparities in the United StatesMarch 7th, 2019

Professional Memberships

American College of Surgeons - ACS
Member
American Society of Clinical Oncology - ASCO
Member
American Society of Breast Surgeons - ASBS
Member
Society of Surgical Oncology
Member

Other Languages

Spanish

Hospital Affiliations

Doctors Hospital of LaredoLaredo, Texas
Methodist HospitalSan Antonio, Texas

GaryWalterUnzeitigMD

Dr. Unzeitig is on Doximity

Education & Training

Certifications & Licensure

Awards, Honors, & Recognition

Clinical Trials

Publications & Presentations

Press Mentions

Professional Memberships

Other Languages

Hospital Affiliations

Viewing the full profile is available to verified healthcare professionals only.